Hyderabad: The final data from the Russian trial of a single-dose vaccine Sputnik Light is expected to be available next week after that the Laboratory of Dr.
Reddy will approach the SEC (the subject of expert committee) to be approved.
Meanwhile, local manufacturing of two vutik v doses is expected to begin in September-October.
“We are now in the process of receiving data on Sputnik Light.
We must be second with updated data after we receive full and final clinical data maybe in about a week and it is something that can ensure the availability of a better vaccine,” MV Ramana , CEO of Branded Markets (India & Emerging Markets), Dr.
Reddy’s laboratory, said on Tuesday.
The company said it would use the Russian 3 phase-3 test data from Sputnik Light for Indian archiving according to SEC recommendations.
Sputnik Light consists of the first adenoviral vector – AD26 – which has demonstrated the temporary efficacy of 79.4% in Russian trials.
SEC, which suggested controller of the Indian Medicine Manager General of India (DCGI), has observed that when Sputnik Light is equal to component-1 of Sputnik-V two doses, where the safety and immunogenicity data has been produced in this country, no need to test Try separately in India.
Deepak Sapra, CEO of Fire & Service, Labor Labor Dr.
Reddy, said local manufacturers Sputnik V is currently in the process of absorption and technology scale.
“We hope that from the September-October period we tend to have sputnik produced locally,” he said during the interaction of virtual media on the sidelines of the results of Q1 for the financial year 2021-22.